Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/07/2025: NAMS (3-star) is a SELL. SELL since 4 days. Profits (-22.08%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 45.63% | Avg. Invested days 42 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.74B USD | Price to earnings Ratio - | 1Y Target Price 45.7 |
Price to earnings Ratio - | 1Y Target Price 45.7 | ||
Volume (30-day avg) 1354942 | Beta - | 52 Weeks Range 14.06 - 27.29 | Updated Date 04/6/2025 |
52 Weeks Range 14.06 - 27.29 | Updated Date 04/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-28 | When - | Estimate -0.4663 | Actual -0.9048 |
Profitability
Profit Margin - | Operating Margin (TTM) -338.47% |
Management Effectiveness
Return on Assets (TTM) -18.19% | Return on Equity (TTM) -46.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 903575785 | Price to Sales(TTM) 38.11 |
Enterprise Value 903575785 | Price to Sales(TTM) 38.11 | ||
Enterprise Value to Revenue 19.83 | Enterprise Value to EBITDA 27.63 | Shares Outstanding 109818000 | Shares Floating 53941411 |
Shares Outstanding 109818000 | Shares Floating 53941411 | ||
Percent Insiders 0.35 | Percent Institutions 99.42 |
Analyst Ratings
Rating 4.5 | Target Price 37 | Buy 5 | Strong Buy 5 |
Buy 5 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Ordinary Shares
Company Overview
History and Background
NewAmsterdam Pharma (NAP) is a biopharmaceutical company focusing on therapies for cardiometabolic diseases. Founded to develop and commercialize obicetrapib, its history is centered around clinical trials and regulatory approvals related to this drug.
Core Business Areas
- Cardiometabolic Disease Therapeutics: Development and commercialization of therapeutics for cardiometabolic diseases, primarily focusing on lowering LDL-cholesterol and reducing cardiovascular risk.
Leadership and Structure
The company is led by a management team with experience in pharmaceutical development and commercialization. The organizational structure includes departments focused on research and development, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Obicetrapib: Obicetrapib is a cholesteryl ester transfer protein (CETP) inhibitor being developed to lower LDL-cholesterol and reduce cardiovascular risk. Clinical trials are underway, and it does not yet have market share or revenue as it is not yet approved. Competitors include statins (e.g., atorvastatin, rosuvastatin) and other LDL-lowering therapies (e.g., PCSK9 inhibitors).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on cardiometabolic diseases is competitive, with significant unmet needs related to LDL-cholesterol management and cardiovascular risk reduction. There is increasing innovation around new therapeutic modalities.
Positioning
NewAmsterdam Pharma aims to position obicetrapib as a differentiated LDL-lowering therapy with the potential for significant cardiovascular risk reduction, potentially offering an advantage over existing statins or PCSK9 inhibitors due to ease of use and efficacy.
Total Addressable Market (TAM)
The TAM for LDL-lowering therapies is substantial, estimated to be in the billions of dollars annually. NewAmsterdam Pharma is positioned to capture a portion of this market with successful development and commercialization of obicetrapib.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (CETP inhibition)
- Potentially significant LDL-cholesterol lowering efficacy
- Strong clinical trial data in development
- Experienced management team
Weaknesses
- Obicetrapib is not yet approved; regulatory risk is high.
- Reliance on a single key product
- Competitive landscape with established therapies
- Commercialization requires significant investment
Opportunities
- Regulatory approval of obicetrapib
- Expansion of clinical indications for obicetrapib
- Partnerships with pharmaceutical companies
- Acquisition by a larger pharmaceutical company
Threats
- Regulatory setbacks or rejection of obicetrapib
- Failure of clinical trials
- Competition from existing and emerging therapies
- Pricing pressures in the pharmaceutical market
Competitors and Market Share
Key Competitors
- AMGN
- MRK
- PFE
- NVO
Competitive Landscape
NewAmsterdam Pharma's advantage lies in its novel mechanism of action (CETP inhibition). The disadvantage is the lack of approved products and competition from established therapies. It must prove that obicetrapib is safe and effective.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily defined by R&D activities and clinical trial progress, prior to commercial product sales.
Future Projections: Future growth depends on regulatory approval of obicetrapib and successful commercialization. Analyst estimates vary based on the likelihood of regulatory success. (Requires real-time analyst data)
Recent Initiatives: Recent initiatives include ongoing clinical trials for obicetrapib and preparations for regulatory submissions.
Summary
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on cardiometabolic diseases, particularly with obicetrapib. It has a novel mechanism of action, but it faces regulatory and commercialization challenges. Successful clinical trials and regulatory approval are key to its future growth, while competitive therapies pose a significant risk. They do not yet have products on the market so success is dependent on their main product being approved by regulatory bodies.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Ordinary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 68 | |
Full time employees 68 | |||
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.